Leukocyte apheresis: Difference between revisions
Content deleted Content added
m →top: Added 1 doi to a journal cite |
m →top: Journal cites:, added 1 PMID |
||
| Line 1: | Line 1: | ||
'''Leukocyte apheresis''' is a medical device therapy (selective [[granulocyte]]/[[monocyte]] adsorptive {GMA} apheresis; GMDN<ref>{{Cite web|url =https://www.gmdnagency.com|title =Global Medical Device Network|url-status =dead|archiveurl =https://web.archive.org/web/20140815063424/https://www.gmdnagency.com/|archivedate =2014-08-15}}</ref> code: 47306) for the treatment of [[inflammation]] of the [[Large intestine|colon]]. It works by removing from the blood a group of [[white blood cells]] called activated [[leukocytes]]<ref>{{Cite journal|url = |title = The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review|last = Hanai H.|date = January 2011|journal = Clinical & Experimental Immunology|doi = 10.1111/j.1365-2249.2010.04279.x|pmid = |access-date = |volume = 163 | issue = 1 |pages = 50–58|display-authors=etal}}</ref> that play a key role in the inflammatory stages of [[ulcerative colitis]] (UC).<ref>{{Cite journal|url = |title = Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation|last = Nikolaus S., Schreiber S.|date = April 1998|journal = Gut|doi = 10.1136/gut.42.4.470|volume = 42|pages = 470–476|display-authors=etal|pmc = 1727082}}</ref> Selectively reducing these cells in the blood helps to reduce inflammation in the colon.<ref>{{Cite journal|url = |title = Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.|last = Muratov V.|date = 2008|journal = Journal of Gastroenterology|doi = |pmid = |access-date = |issue = 43|pages = 277–282|display-authors=etal}}</ref> Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.<ref>{{Cite web|url = https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p511-efficacy-and-safety-of-granulocytemonocyte-adsorptive-apheresis-in-steroid-dependent-active-ulcerative-colitis-with-insufficient-response-or-intolerance-to-immunosuppressants-andor-biological-therapies-the-art-trial-results-at-24-and-48-weeks.html?highlight=YToxOntpOjA7czo5OiJhZGFjb2x1bW4iO30|title = P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks|date = 2015|access-date = |website = ecco-ibd.eu|publisher = The European Crohn's and Colitis Organisation (ECCO)|last = Dignass A.|display-authors=etal}}</ref> |
'''Leukocyte apheresis''' is a medical device therapy (selective [[granulocyte]]/[[monocyte]] adsorptive {GMA} apheresis; GMDN<ref>{{Cite web|url =https://www.gmdnagency.com|title =Global Medical Device Network|url-status =dead|archiveurl =https://web.archive.org/web/20140815063424/https://www.gmdnagency.com/|archivedate =2014-08-15}}</ref> code: 47306) for the treatment of [[inflammation]] of the [[Large intestine|colon]]. It works by removing from the blood a group of [[white blood cells]] called activated [[leukocytes]]<ref>{{Cite journal|url = |title = The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review|last = Hanai H.|date = January 2011|journal = Clinical & Experimental Immunology|doi = 10.1111/j.1365-2249.2010.04279.x|pmid = |access-date = |volume = 163 | issue = 1 |pages = 50–58|display-authors=etal}}</ref> that play a key role in the inflammatory stages of [[ulcerative colitis]] (UC).<ref>{{Cite journal|url = |title = Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation|last = Nikolaus S., Schreiber S.|date = April 1998|journal = Gut|doi = 10.1136/gut.42.4.470|volume = 42|pages = 470–476|display-authors=etal|pmc = 1727082|pmid=9616306}}</ref> Selectively reducing these cells in the blood helps to reduce inflammation in the colon.<ref>{{Cite journal|url = |title = Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.|last = Muratov V.|date = 2008|journal = Journal of Gastroenterology|doi = |pmid = |access-date = |issue = 43|pages = 277–282|display-authors=etal}}</ref> Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.<ref>{{Cite web|url = https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p511-efficacy-and-safety-of-granulocytemonocyte-adsorptive-apheresis-in-steroid-dependent-active-ulcerative-colitis-with-insufficient-response-or-intolerance-to-immunosuppressants-andor-biological-therapies-the-art-trial-results-at-24-and-48-weeks.html?highlight=YToxOntpOjA7czo5OiJhZGFjb2x1bW4iO30|title = P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks|date = 2015|access-date = |website = ecco-ibd.eu|publisher = The European Crohn's and Colitis Organisation (ECCO)|last = Dignass A.|display-authors=etal}}</ref> |
||
==References== |
==References== |
||
Revision as of 09:24, 30 December 2019
Leukocyte apheresis is a medical device therapy (selective granulocyte/monocyte adsorptive {GMA} apheresis; GMDN[1] code: 47306) for the treatment of inflammation of the colon. It works by removing from the blood a group of white blood cells called activated leukocytes[2] that play a key role in the inflammatory stages of ulcerative colitis (UC).[3] Selectively reducing these cells in the blood helps to reduce inflammation in the colon.[4] Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.[5]
References
- ^ "Global Medical Device Network". Archived from the original on 2014-08-15.
- ^ Hanai H.; et al. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology. 163 (1): 50–58. doi:10.1111/j.1365-2249.2010.04279.x.
- ^ Nikolaus S., Schreiber S.; et al. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut. 42: 470–476. doi:10.1136/gut.42.4.470. PMC 1727082. PMID 9616306.
- ^ Muratov V.; et al. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis". Journal of Gastroenterology (43): 277–282.
- ^ Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO).
